TRANSACTION REPORT · SEC DISCLOSURES
Deal notes
ContextDeal context
This is an ATM facility event. The capacity shown is not cash raised.
Gross proceedsNo cash proceeds
Offering price—
Discount to prior close—
Warrant coverage—
Sales agentLeerink Partners LLC
Transaction overview
01Pyxis Oncology, Inc. disclosed an at-the-market program event: sales suspended. Available capacity is $0.00. This event does not record cash proceeds raised.
- Financing type
- ATM
- Announcement date
- —
- SEC disclosure date
- Sep 29, 2026
- Agreement date
- Nov 26, 2025
- Pricing date
- —
- Closing date
- —
- Filing date
- Sep 29, 2026
- Status
- Announced
- Market cap before SEC disclosure
- $185.6M
- Prior closing price
- $2.90
- Raise as % of market cap
- —
Market data · FMP
- Historical market cap
- $185,575,666
- Market date
- Sep 28, 2026
- Closing price
- $2.90
- Latest reported shares outstanding
- 63,355,480
- Latest reported float shares
- 37,251,756
- Share-data date
- Oct 1, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Oct 1, 2026.
Financial Modeling Prep ↗Financing terms
02At-the-market program
- Capital event
- Sales suspended
- Available capacity
- $0.00
- Proceeds raised
- Not reported as raised
- Shares sold
- —
- Average sale price
- —
- Relevant period
- Not applicable
- Sales commission
- —
Fees & transaction economics
03- Placement agent / underwriting fee
- —
- Agent fee amount
- —
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
Transaction participants
04IssuerPyxis Oncology, Inc.Issuer
Investor names: —
Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
EX-5.2 · Pyxis Oncology, Inc.SEC filing · Nov 26, 2025
Open source ↗EX-5.1 · Pyxis Oncology, Inc.SEC filing · Nov 26, 2025
Open source ↗EX-4.1 · Pyxis Oncology, Inc.SEC filing · Nov 26, 2025
Open source ↗EX-1.2 · Pyxis Oncology, Inc.SEC filing · Nov 26, 2025
Open source ↗S-3 · Pyxis Oncology, Inc.SEC filing · Nov 26, 2025
Open source ↗424B5 · Pyxis Oncology, Inc.SEC filing · Sep 29, 2026
Open source ↗FMP historical market data · PYXSMarket data · Sep 28, 2026
Open source ↗Filing evidence & original calculations
status
Announced
The date of this Supplement No. 1 to the Prospectus Supplement is September 29, 2026.Original source ↗
atm Event
Sales suspended
We will not make any sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus supplement relating to such sales is filedOriginal source ↗
SEC disclosure date
2026-09-29
pyxs20260909c_424b5.htm SUPPLEMENT NO. 1 DATED SEPTEMBER 29, 2026 TO PROSPECTUS SUPPLEMENT DATED NOVEMBER 26, 2025 Filed pursuant to Rule 42Original source ↗
date Basis
sec_disclosure
pyxs20260909c_424b5.htm SUPPLEMENT NO. 1 DATED SEPTEMBER 29, 2026 TO PROSPECTUS SUPPLEMENT DATED NOVEMBER 26, 2025 Filed pursuant to Rule 42Original source ↗
atm Capacity Basis
Available capacity
no further shares of our common stock may be offered or sold under the Prospectus SupplementOriginal source ↗
market Cap
FMP reported market cap; as of 2026-09-28.
{"provider": "FMP", "symbol": "PYXS", "date": "2026-09-28", "marketCap": 185575666}Original source ↗